These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20404746)

  • 21. Surgical treatment of myogenic blepharoptosis.
    De Wilde F; D'Haens M; Smet H; Martin JJ; Tassignon MJ
    Bull Soc Belge Ophtalmol; 1995; 255():139-46. PubMed ID: 7496569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pompe disease, the must-not-miss diagnosis: A report of 3 patients.
    Dubrovsky A; Corderi J; Karasarides T; Taratuto AL
    Muscle Nerve; 2013 Apr; 47(4):594-600. PubMed ID: 23463700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and histologic ocular findings in pompe disease.
    Yanovitch TL; Banugaria SG; Proia AD; Kishnani PS
    J Pediatr Ophthalmol Strabismus; 2010; 47(1):34-40. PubMed ID: 20128552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early pathologic changes and responses to treatment in patients with later-onset Pompe disease.
    Chien YH; Lee NC; Huang PH; Lee WT; Thurberg BL; Hwu WL
    Pediatr Neurol; 2012 Mar; 46(3):168-71. PubMed ID: 22353292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
    van Capelle CI; van der Beek NA; Hagemans ML; Arts WF; Hop WC; Lee P; Jaeken J; Frohn-Mulder IM; Merkus PJ; Corzo D; Puga AC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2010 Dec; 20(12):775-82. PubMed ID: 20817528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
    Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D
    Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of Pompe disease treated with acid alpha-glucosidase].
    Kapica-Topczewska K; Tarasiuk J; Kułakowska A; Drozdowski W
    Neurol Neurochir Pol; 2008; 42(4):353-7. PubMed ID: 18975241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
    van Capelle CI; Winkel LP; Hagemans ML; Shapira SK; Arts WF; van Doorn PA; Hop WC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2008 Jun; 18(6):447-52. PubMed ID: 18508267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pompe disease: a neuromuscular disease with respiratory muscle involvement.
    Mellies U; Lofaso F
    Respir Med; 2009 Apr; 103(4):477-84. PubMed ID: 19131232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice.
    Hesselink RP; Gorselink M; Schaart G; Wagenmakers AJ; Kamphoven J; Reuser AJ; Van Der Vusse GJ; Drost MR
    Muscle Nerve; 2002 Jun; 25(6):873-83. PubMed ID: 12115977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.
    Chien YH; Lee NC; Huang HJ; Thurberg BL; Tsai FJ; Hwu WL
    J Pediatr; 2011 Jun; 158(6):1023-1027.e1. PubMed ID: 21232767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.